LYEL vs RGP Comparison

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Resources Connection Inc is a professional services firm. Its segments include On-Demand Talent provides businesses with a go-to source for bringing in experts when its needed, serving the office of the CFO; Consulting drives transformation across people, processes and technology across domain areas including finance, technology and digital, risk and compliance and operational performance; Europe & Asia Pacific offers both on-demand and consulting services to clients throughout Europe and Asia Pacific; Outsourced Services; and Sitrick. It derives the majority of revenue from On-Demand Talent segment. Geographically, it operates in United States and internationally.